Genosco’s current pipeline consists of three assets in the clinical stage, and two assets
in the pre-clinical stage. Our core competence comes from its know-how in generating selective
kinase inhibitor of interest.
Lazertinib (GNS-1480), an EGFR mutant-selective inhibitor for non-small cell lung cancer
(NSCLC) and its metastatic brain cancer, is in clinical phase 3 study. This program is our most
advanced pipeline and has been licensed out to Yuhan Corporation.
SKI-O-703, a selective SYK inhibitor for rheumatoid arthritis (RA), and idiopathic thrombocytopenic
purpura (ITP), is in clinical phase 2 study.
SKI-G-801, an FLT3 inhibitor for acute myeloid leukemia is in clinical phase 1 study.
FGFR4 program for hepatocellular carcinoma is in the lead optimization stage. This
program has been licensed out to Yuhan Corporation.
ROCK2 and FGFR2/3 programs are in the lead optimization stage.